Table 1

Baseline data from 250 female and male overweight and obese participants

Parameter

Evaluable N1

Mean(SD)


Age (y)

243

47.6(11.6)

Weight (kg)

243

97.3(18.2)

Height (cm)

243

166(8)

Body mass index (kg/m2)

243

35.4(5.2)

Body fat (%)

243

38.2(6.6)

2Waist (cm)

243

100.4(12.8)

2Systolic blood pressure (mmHg)

243

123(18)

2Diastolic blood pressure (mmHg)

243

70(10)

2Triglyceride (mmol/L)

243

1.56(0.82)

2High density lipoprotein-cholesterol (mmol/L)

243

1.33(0.34)

2Fasting plasma glucose (mmol/L)

234

5.32(1.38)

Haemoglobin A1c (%)

217

5.25(0.82)

2Metabolic syndrome marker count

234

2.4(1.1)

Vitamin D3nmol/L*

Total

243

62.2(22.7)

Women

200

62.4(21.9)

Men

43

61.7(26.3)

Skin pigment, light

206

64.8(22.0)

Skin pigment, variable

37

47.5(20.0)

Summer

141

68.7(21.9)

Winter

102

53.3(20.6)

2Metabolic syndrome, no

135

61.4(22.8)

2Metabolic syndrome, yes

99

63.8(22.4)

Non-type II diabetes mellitus

223

62.7(22.7)

Type II diabetes mellitus

11

55.5(20.1)


* Raw data in pair sets. See text for multivariable regression results. 1Although anthropometry was collected on all 250 participants, data is only shown for 243, as evaluable serum samples for vitamin D3 analysis were available for this number (N) only. 6 samples were not obtained due to unsuccessful venepuncture and 1 sample was lost in transit to the laboratory. For the sub-groups some samples were not evaluable due to sample quality or loss. Sample number (N) is shown for each category. 2 Metabolic syndrome (N=234) is defined by the International Diabetes Federation as 1) Waist circumference: Europids and Undefined groups [such as Maori and Pacific Peoples] ≥ 94 cm (men), ≥ 80 cm (women), Asian (based on a Chinese, Malay and Indian Asian population) ≥ 90 cm (men) and ≥ 80 cm (women). Waist must be included, plus two or more of 2) Systolic and diastolic blood pressure ≥ 130/85 mmHg, 3) High density lipoprotein – cholesterol <1.03 mmol/L (<40 mg/dL) men, <1.29 mmol/L (<50 mg/dL) women 4) Triglyceride ≥ 1.69 mmol/L (150 mg/dL) 5) Fasting plasma glucose ≥ 5.6 mmol/L (≥ 100 mg/dL) and/or on treatment medication for the latter 4 conditions.

McGill et al. Nutrition Journal 2008 7:4   doi:10.1186/1475-2891-7-4

Open Data